Medartis Group Reports Strong H1 2026 Sales Growth

Medartis Holding AG announced impressive organic sales growth of 17.0% for the first half of 2026, reaching CHF 160.8 million. This growth was bolstered by significant market advancements in the US and EMEA regions. The company's core EBITDA margin improved to 18.0%, despite challenges from currency fluctuations and increased US tariffs.

The EMEA region experienced a 42.5% increase in sales, with Austria, Poland, Spain, and the UK expanding their market shares. In the US, core sales achieved 27.4% growth, primarily driven by the rollout of the TOUCH prosthesis. The APAC region saw sales rise to CHF 17.8 million, with notable progress in Australia and Japan.

Medartis projects further organic growth of 17%-19% for the entire year, underpinned by ongoing market expansions and product rollouts. The company is actively positioning itself for continued success, focusing on strategic investments and operational efficiencies.